睿知中国疾病研究地图
候选清单0

扬州

江苏省苏北人民医院

Northern Jiangsu People's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 9 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

江苏省苏北人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma5 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma19 篇牵头论文牵头 4 项开放试验
  3. 胃癌Stomach cancer47 篇牵头论文牵头 1 项开放试验
  4. 骨肉瘤Osteosarcoma3 篇牵头论文
  5. 胃肠道间质瘤Gastrointestinal stromal tumour3 篇牵头论文
  6. 血友病 AHaemophilia A0 篇牵头论文
  7. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  8. IgA 肾病IgA nephropathy2 篇牵头论文
  9. 成骨不全症Osteogenesis imperfecta1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

扬州有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术分子标志物与基因
牵头的论文5
  1. Development of a nomogram based on body composition and tumor burden indicators to predict lymph node metastasis in patients with T1 esophageal squamous cell carcinoma.2025BMC cancer免费全文
  2. Nomogram based on a novel nutritional immune-inflammatory status score to predict postoperative outcomes in esophageal squamous cell carcinoma.2025World journal of gastroenterology免费全文
  3. Combining fecal microbiome and metabolomics reveals diagnostic biomarkers for esophageal squamous cell carcinoma.2024Microbiology spectrum免费全文
  4. PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling.2023BMC cancer免费全文
  5. Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma.2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology
中文论文(未计入)1
  1. [Progress in autoantibodies associated with esophageal squamous cell carcinoma].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  2. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  3. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  6. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  7. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  8. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)12
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Figshare补充材料
  3. Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio2025Figshare论文
  4. Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  5. Preoperative Immunotherapy Combined with Chemotherapy: Evaluation of Nutritional and Immune-inflammatory Status in ESCC and Its Impact on Perioperative Period2024Research Square预印本
  6. WITHDRAWN: Clinical characterization and immunosuppressive regulation of DNAJCB5B in Esophageal Squamous Cell Carcinoma2024Research Square预印本
  7. WITHDRAWN: Clinical characterization and immunosuppressive regulation of DNAJCB5B in Esophageal Squamous Cell Carcinoma2024Research Square预印本
  8. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Research会议摘要
  9. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  10. P-100 CXCL8 is a valid potential prognostical marker for esophageal squamous cell carcinoma2022Annals of Oncology会议摘要
  11. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  12. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.1%。

牵头论文
19
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 7720242025: 882025

扬州有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07811687

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:江苏省苏北人民医院扬州

  2. 正在招募
    Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
    分期
    II期
    开始
    2025-09
    登记号
    NCT07337421

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:江苏省苏北人民医院扬州

  3. 正在招募
    Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
    分期
    II期
    开始
    2025-11
    登记号
    NCT07337460

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:江苏省苏北人民医院扬州

  4. 正在招募
    CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
    分期
    不分期
    开始
    2022-05
    登记号
    NCT05433467

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省苏北人民医院扬州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)复发与预后影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科
牵头的论文19
  1. Integrative Analysis the Role of ENG as a Metabolic and Macrophage-Related Gene in Hepatocellular Carcinoma.2026Biochemical genetics
  2. Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.2025BMC medical imaging免费全文
  3. MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis.2025Cell death & disease免费全文
  4. CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling.2025Cell death & disease免费全文
  5. Cross-talks of GSH, mitochondria, RNA m6A modification, NRF2, and p53 between ferroptosis and cuproptosis in HCC: A review.2025International journal of biological macromolecules
  6. Amide proton transfer-weighted MRI distinguishes hepatocellular carcinoma from mass-forming intrahepatic cholangiocarcinoma.2025Magnetic resonance imaging
  7. FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling.2025Medical oncology (Northwood, London, England)
  8. Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential.2025Medical oncology (Northwood, London, England)
  9. Enhanced prediction of 5-year postoperative recurrence in hepatocellular carcinoma by incorporating LASSO regression and random forest models.2025Surgical endoscopy
  10. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.2024Cardiovascular and interventional radiology
  11. Transarterial chemoembolization combined with microwave ablation versus repeated resection for recurrent small hepatocellular carcinoma after resection: What is the better treatment?2024Clinical radiology
  12. TRIM5 as a promising diagnostic biomarker of hepatocellular carcinoma: integrated analysis and experimental validation.2024Functional & integrative genomics
  13. Identification of Antisense RNA NRAS-AS and Its Preliminary Exploration of the Anticancer Regulatory Mechanism.2024Genes免费全文
  14. Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma.2024Journal for immunotherapy of cancer免费全文
  15. Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  16. Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  17. RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.2023Cell communication and signaling : CCS免费全文
  18. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.2021Experimental cell research
  19. Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml.2021Frontiers in public health免费全文
中文论文(未计入)1
  1. [Study on the correlation between high expression of GIT1 and M2 macrophage infiltration and prognosis in hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function正在招募NCT07811687牵头方2026-08 启动
  2. Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors正在招募NCT07337421牵头方II期2025-09 启动
  3. Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors正在招募NCT07337460牵头方II期2025-11 启动
  4. CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection正在招募NCT05433467牵头方不分期2022-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 47 篇,占 0.5%。

牵头论文
47
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 9920232024: 181820242025: 16162025

扬州有 1 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
    分期
    不分期
    开始
    2025-01
    登记号
    NCT06741501

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:江苏省苏北人民医院扬州

  2. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术影像与人工智能早期发现与内镜
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科
牵头的论文47
  1. IKZF3 promotes gastric cancer progression via Hedgehog signaling activation and is targetable by SANT-1.2025Acta biochimica et biophysica Sinica免费全文
  2. ASO Author Reflections: Unlocking the Potential of Noncoding RNAs in Gastric Cancer: From Molecular Insights to Precision Treatment.2025Annals of surgical oncology
  3. ncRNAs as Key Regulators in Gastric Cancer: From Molecular Subtyping to Therapeutic Targets.2025Annals of surgical oncology
  4. PWP1 transcriptionally regulates p53, modulating apoptosis and cell cycle to promote gastric cancer progression.2025Apoptosis : an international journal on programmed cell death免费全文
  5. A comparison of postoperative outcomes between robotic-assisted and laparoscopic-assisted total gastrectomy: a comprehensive meta-analysis and systematic review.2025BMC surgery免费全文
  6. Exosomes play a crucial role in remodeling the tumor microenvironment and in the treatment of gastric cancer.2025Cell communication and signaling : CCS免费全文
  7. Targeted therapy for KIF3C: A study on the mechanism of combined therapy with KIF3C signaling pathway, afatinib, and MT-DC (ac)phosphoramide in regulating gastric cancer cell proliferation.2025Cellular signalling
  8. A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  9. A 3-Arm case-matched analysis of anti-reflux reconstruction methods after laparoscopic proximal gastrectomy - Single tract jejunal interposition vs double tract reconstruction vs tube-like stomach reconstruction.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyRCT
  10. Long-term muscle-sparing benefits of proximal gastrectomy in elderly patients with upper-third early gastric cancer: A propensity score-matched analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Evaluation of combined tubular gastroesophageal anastomosis and C-shaped flap technique in proximal gastrectomy for gastric cancer: A retrospective propensity score matching analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. Development and external validation of nomogram associated with gastroparesis syndrome after subtotal gastrectomy depending on random forest and traditional model: does robotic surgery have advantages?2025Journal of robotic surgery
  13. The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates.2025Molecular cancer免费全文
  14. Development and validation of a prognostic model for cachexia in postoperative gastric cancer patients with low nutritional risk: a dual-center retrospective cohort study.2025Surgical endoscopy
  15. Comparison of channel esophagogastrostomy and double tract reconstruction after laparoscopic-assisted proximal gastrectomy: a propensity score-matched analysis.2025Surgical endoscopy
  16. Nomogram for pre-procedural prediction of lymph node metastasis in patients with submucosal early gastric cancer.2025Surgical endoscopy
  17. PACSIN1 promotes immunosuppression in gastric cancer by degrading MHC-I.2024Acta biochimica et biophysica Sinica免费全文
  18. FANCA facilitates G1/S cell cycle advancement, proliferation, migration and invasion in gastric cancer.2024Acta biochimica et biophysica Sinica免费全文
  19. Sentinel Node Navigation Surgery for Early Gastric Cancer: A Narrative Review.2024American journal of clinical oncology
  20. R-type gastrojejunostomy after total laparoscopic radical gastrectomy for distal gastric cancer.2024Asian journal of surgery
  21. GGT5 facilitates migration and invasion through the induction of epithelial-mesenchymal transformation in gastric cancer.2024BMC medical genomics免费全文
  22. Modified Q-type purse-string suture duodenal stump embedding method for laparoscopic gastrectomy for gastric cancer.2024BMC surgery免费全文
  23. ACTL8 Promotes the Progression of Gastric Cancer Through PI3K/AKT/mTOR Signaling Pathway.2024Digestive diseases and sciences免费全文
  24. BHLHE40-mediated transcriptional activation of GRIN2D in gastric cancer is involved in metabolic reprogramming.2024Functional & integrative genomics
  25. Helicobacter pylori Therapy and Risk of Gastric Cancer After Endoscopic Resection of Dysplasia: A Sensitivity Analysis Assessing Impact of Unmeasured Confounding.2024Gastroenterology
  26. Transcription Factor E2F4 Promote Proliferation, Migration, and Invasion of Gastric Cancer Cells by transcriptionally activating DSCC1.2024International journal of biological sciences免费全文
  27. The benefits of R anastomotic technique for Billroth-II reconstruction with Braun anastomosis during totally laparoscopic distal gastrectomy: a propensity score matching analysis.2024International journal of surgery (London, England)免费全文
  28. Analysis of Clinical Efficacy and Quality of Life of Braun Anastomosis in Gastrointestinal Reconstruction in Totally Laparoscopic Distal Gastrectomy: A Single-Center Retrospective Study.2024Journal of gastrointestinal cancer
  29. Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.2024Journal of gastrointestinal cancer
  30. Upper abdominal pain in a young female treated by endoscopic submucosal dissection.2024Revista espanola de enfermedades digestivas
  31. An unusual cause of life-threatening upper gastrointestinal bleeding.2024Revista espanola de enfermedades digestivas
  32. Surgical options and survival prognosis in geriatric patients beyond average lifespan with locally advanced gastric cancer: a propensity score-matched analysis.2024Surgical endoscopy
  33. A retrospective study of provisional outcomes of intracorporeal esophagojejunostomy versus extracorporeal anastomosis during laparoscopic total gastrectomy for gastric cancer. a single -center.2024World journal of surgical oncology免费全文
  34. Laparoscopic versus open distal gastrectomy for advanced gastric cancer in elderly patients: a propensity-score matched analysis.2024World journal of surgical oncology免费全文
  35. Single-port versus conventional laparoscopic distal gastrectomy for gastric cancer: A systematic review and meta analysis.2023Asian journal of surgery
  36. Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer.2023BMC bioinformatics免费全文
  37. Surgical outcomes of laparoscopic proximal gastrectomy for upper-third gastric cancer: esophagogastrostomy, gastric tube reconstruction, and double-tract reconstruction.2023BMC surgery免费全文
  38. Endoscopic submucosal dissection of a rare cardiac mass in an older woman: dendritic fibromyxolipoma.2023Gastrointestinal endoscopy
  39. Machine learning and single-cell sequencing reveal the potential regulatory factors of mitochondrial autophagy in the progression of gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  40. An unusual gastric mass mimicking a gastrointestinal stromal tumor.2023Revista espanola de enfermedades digestivas
  41. Endoscopic submucosal dissection of a rare antral mass: gastric fibrolipoma.2023Revista espanola de enfermedades digestivas
  42. Endoscopic full-thickness resection of a complete extraluminal growth gastric gastrointestinal stromal tumor with a single-channel gastroscope.2023Revista espanola de enfermedades digestivas
  43. A nomogram for predicting the recurrence of small bowel obstruction after gastrectomy in patients with gastric cancer.2023World journal of surgical oncology免费全文
  44. The UPR signaling molecule ATF6 is a poor prognostic marker in gastric cancer.2022Asian journal of surgery
  45. Neutrophil-lymphocyte ratio combined with plasma fibrinogen is an useful predictor for the diagnosis of liver metastases from gastric cancer.2022Asian journal of surgery
  46. Galectin‑1 binds GRP78 to promote the proliferation and metastasis of gastric cancer.2022International journal of oncology免费全文
  47. A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).2021International journal of surgery (London, England)
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy状态不明NCT06475170牵头方不分期2024-08 启动
  2. Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer状态不明NCT06405009牵头方2024-04 启动
  3. Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy in Totally Laparoscopic Total Gastrectomy状态不明NCT06383793牵头方2024-04 启动
  4. PWP1's Expression in Gastric Cancer.已完成NCT06392750牵头方2021-05 启动
  5. Comparison of Channel Esophagogastrostomy and Double Tract Reconstruction After Laparoscopic-assist Proximal Gastrectomy: A Propensity Score-Matched Analysis已完成NCT06741124牵头方2020-09 启动
  6. Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy即将招募NCT06741501牵头方(推断)不分期2025-01 启动
  7. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  8. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  9. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  10. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  11. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  12. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  13. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  14. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

扬州有 3 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

扬州有 1 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

扬州有 1 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  2. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

扬州有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别肾脏、腹膜后与血管
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

扬州有 1 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文2
  1. Clinicopathological features and renal outcomes in patients with IgA nephropathy secondary to psoriasis.2025Clinical and experimental medicine
  2. The Role of Renal Macrophage, AIM, and TGF-β1 Expression in Renal Fibrosis Progression in IgAN Patients.2021Frontiers in immunology
早期论文(2016–2020 年)1
  1. Comparison of secondary IgA nephropathy in patients with ankylosing spondylitis and rheumatoid arthritis.2020Modern rheumatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

扬州有 1 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

江苏省苏北人民医院

Northern Jiangsu People's Hospital

扬州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Northern Jiangsu People's Hospital Affiliated to Yangzhou University; Subei People's Hospital of Jiangsu Province; Subei People's Hospital; Northern Jiangsu People's Hospital Affliated to Yangzhou University; Northern Jiangsu People's Hospital (Clinical Medical College; Northern Jiangsu people's Hospital; Medical Research Center of Northern Jiangsu People's Hospital; Affiliated Hospital to Yangzhou University

提出更正下载数据